Gefitinib Enhances the Anti‑tumor Immune Response Against EGFR‑mutated NSCLC by Upregulating B7H5 Expression and Activating T Cells Via CD28H

Huihui Guo,Xilin Zhang,Shangzhi Xie,Tianwei Chen,Dong Xie,Ying Cai,Dawei Cui,Liang Wang,Wei Chen, Xiang Wang

International journal of oncology（2022）

引用 0|浏览19

暂无评分

关键词

gefitinib,CD28H,NSCLC,EGFR mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要